1. No category

2.7.5 参考文献
2.7.5
参考文献
［1］Siegel JN, Zhen BG. Use of the American College of Rheumatology N (ACR-N) index of
improvement in rheumatoid arthritis: argument in favor. Arthritis Rheum 2005;52(6):1637-41.
［2］St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination
of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled
trial. Arthritis Rheum 2004;50(11):3432-43.
［3］Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic
effect of the combination of etanercept and methotrexate compared with each treatment alone in
patients
with
rheumatoid
arthritis:
double-blind
randomised
controlled
trial.
Lancet
2004;363(9410):675-81.
［4］Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A
comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J
Med 2000;343(22):1586-93.
［5］Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al.
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination
therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in
patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate
treatment. Arthritis Rheum 2006;54(1):26-37.
［6］Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of
rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant
Therapy Study Group. N Engl J Med. 2000;343(22):1594-602.
［7］van der Heijde D, Landewe R, Klareskog L, Rodriguez-Valverde V, Settas L, Pedersen R, et al.
Presentation and analysis of data on radiographic outcome in clinical trials: experience from the
TEMPO study. Arthritis Rheum 2005;52(1):49-60.
［8］Rahman MU, Strusberg I, Geusens P, Berman A, Yocum D, Baker D, et al. Double-blinded
infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007.
［9］Landewe R, van der Heijde D. Radiographic progression depicted by probability plots: presenting
data with optimal use of individual values. Arthritis Rheum 2004;50(3):699-706.
［10］Lindqvist E, Jonsson K, Saxne T, Eberhardt K. Course of radiographic damage over 10 years in a
cohort with early rheumatoid arthritis. Ann Rheum Dis 2003;62(7):611-6.
［11］Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of
radiographic progression. Arthritis Rheum 1998;41(9):1571-82.
［12］Gordon P, West J, Jones H, Gibson T. A 10 year prospective followup of patients with rheumatoid
arthritis 1986-96. J Rheumatol 2001;28(11):2409-15.
［13］Strand V, Sharp JT. Radiographic data from recent randomized controlled trials in rheumatoid
arthritis: what have we learned? Arthritis Rheum 2003;48(1):21-34.
348
2.7.5 参考文献
［14］Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important
difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol
1993;20(3):557-60.
［15］Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE, Jr. Determining minimally important
changes in generic and disease-specific health-related quality of life questionnaires in clinical
trials of rheumatoid arthritis. Arthritis Rheum 2000;43(7):1478-87.
［16］日本呼吸器学会市中肺炎診療ガイドライン作成委員会．肺炎の重症度分類と入院，外
来治療の目安．日本呼吸器学会「呼吸器感染症に関するガイドライン」成人市中肺炎治療
の基本的考え方．東京：日本呼吸器学会；2002.p.20-1.
349